SELLAS Life Sciences (SLS) Intangibles (2014 - 2017)
SELLAS Life Sciences (SLS) reported Intangibles of $17.6 million for Q4 2017, up 90.17% year-over-year from $9.3 million in Q4 2016, and up 117.28% on a QoQ basis from $8.1 million in Q3 2017.
SELLAS Life Sciences (SLS) has 4 years of Intangibles data on file, last reported at $17.6 million in Q4 2017.
- Quarterly Intangibles rose 90.17% year-over-year to $17.6 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $17.6 million (up 90.17% YoY) and the FY2017 annual result came in at $17.6 million, up 90.17% from the prior year.
- Intangibles climbed to $17.6 million in Q4 2017 per SLS's latest filing, from $8.1 million in the prior quarter.
- Across five years, Intangibles topped out at $17.6 million in Q4 2017 and bottomed at $2.1 million in Q1 2014.
- The 4-year median for Intangibles is $9.3 million (2014), against an average of $8.8 million.
- The widest annual swing landed in 2015, when Intangibles jumped 338.63%; it then declined 12.48% in 2017.
- Tracing SLS's Intangibles over 4 years: stood at $9.3 million in 2014, then changed by 0.0% to $9.3 million in 2015, then changed by 0.0% to $9.3 million in 2016, then jumped by 90.17% to $17.6 million in 2017.
- Per Business Quant, the three latest SLS Intangibles figures stand at $17.6 million (Q4 2017), $8.1 million (Q3 2017), and $9.3 million (Q2 2017).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 4.41 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 11,640.44 |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 418.50 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.29 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 17.60 Mn |
| Sep 30, 2017 | 8.10 Mn |
| Jun 30, 2017 | 9.26 Mn |
| Mar 31, 2017 | 9.26 Mn |
| Dec 31, 2016 | 9.26 Mn |
| Sep 30, 2016 | 9.26 Mn |
| Jun 30, 2016 | 9.26 Mn |
| Mar 31, 2016 | 9.26 Mn |
| Dec 31, 2015 | 9.26 Mn |
| Sep 30, 2015 | 9.26 Mn |
| Jun 30, 2015 | 9.26 Mn |
| Mar 31, 2015 | 9.26 Mn |
| Dec 31, 2014 | 9.26 Mn |
| Sep 30, 2014 | 9.16 Mn |
| Jun 30, 2014 | 2.32 Mn |
| Mar 31, 2014 | 2.11 Mn |